Evidence mapPaperPMID 39769330Full record

ReviewInternational journal of molecular sciences2024

The Balance of Ketoacids α-Ketoglutarate and α-Ketoglutaramate Reflects the Degree of the Development of Hepatoencephalopathy in Rats.

Yevgeniya I Shurubor, Anton A Keskinov, Vladimir S Yudin, Boris F Krasnikov

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yevgeniya I ShuruborCentre for Strategic Planning of FMBA of the Russian Federation, Pogodinskaya St., Bld. 10, 119121 Moscow, Russia.ORCID 0000-0003-4060-3087
Anton A KeskinovCentre for Strategic Planning of FMBA of the Russian Federation, Pogodinskaya St., Bld. 10, 119121 Moscow, Russia.
Vladimir S YudinCentre for Strategic Planning of FMBA of the Russian Federation, Pogodinskaya St., Bld. 10, 119121 Moscow, Russia.ORCID 0000-0002-9199-6258
Boris F KrasnikovCentre for Strategic Planning of FMBA of the Russian Federation, Pogodinskaya St., Bld. 10, 119121 Moscow, Russia.ORCID 0000-0001-9525-4385

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatoencephalopathy (HE) is a liver disease that can lead to brain pathology and the impairment of human cognitive abilities. The objective assessment of HE disease severity is difficult due to the lack of reliable diagnostic markers. This paper examines the background to the emergence of HE markers and provides a brief overview of research results indicating the diagnostic value of potential markers isolated from a wide range of metabolites analyzed. It has been suggested that metabolites of the glutamate-glutamine (Glu-Gln) cycle, α-ketoglutarate (αKG), and α-ketoglutaramate (αKGM) can act as such markers of HE. The informative value of these markers was revealed during a comparative analysis of the distribution of αKG and αKGM in samples of the blood plasma and tissues (liver, kidneys, and brain) of rats exposed to the strong hepatotoxin thioacetamide (TAA). A comparative analysis of the balance of αKG and αKGM, as well as their ratio (αKG/αKGM) in the examined samples of blood plasma and animal tissues in these models, revealed their diagnostic value for assessing the severity of HE and/or monitoring the recovery process.

Indexed as

Hepatic EncephalopathyKetoglutaric AcidsAnimalsBiomarkersBrainDisease Models, AnimalGlutaratesHumansLiverRatsalpha-ketoglutaramateBiomarkersGlutaratesKetoglutaric Acidsbiomarkerhepatoencephalopathyα-ketoglutaramateα-ketoglutarate

Identifiers

PMID39769330
PMCPMC11677448

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.